Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yahalom, J.
Right arrow Articles by Mauch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yahalom, J.
Right arrow Articles by Mauch, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:79-83, 2002
© 2002 European Society for Medical Oncology

The involved field is back: issues in delineating the radiation field in Hodgkin's disease

J. Yahalom1 and P. Mauch2

1 Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 2 Brigham and Women's Hospital, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Abstract

During the last century, the role of radiation therapy in the treatment of Hodgkin's disease (HD) has changed drastically. From a palliative treatment reserved for bulky lymph nodes of an incurable disease at the beginning of the century, to an exciting primary treatment used alone to cure most stages in the 1960s and 1970s, to the present more limited role as consolidation treatment after chemotherapy. Interestingly, the radiation field size has always influenced the evolution of treatment principles of HD. Over several decades, large or extended field radiotherapy has become synonymous with the successful treatment of HD. But the critical transformation from a single-modality to a combined-modality therapy, together with improvement in imaging and radiation planning techniques, mandates a reassessment of the delineation of appropriate radiation fields in HD. In this manuscript we review the comeback of the involved field, address design questions and offer field borders for common disease sites.

Hodgkin's disease; involved field; radiation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
B. S. Hoppe, C. H. Moskowitz, D. A. Filippa, C. S. Moskowitz, T. Kewalramani, A. D. Zelenetz, and J. Yahalom
Involved-Field Radiotherapy Before High-Dose Therapy and Autologous Stem-Cell Rescue in Diffuse Large-Cell Lymphoma: Long-Term Disease Control and Toxicity
J. Clin. Oncol., April 10, 2008; 26(11): 1858 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. A. Macdonald, K. Ding, M. K. Gospodarowicz, W. A. Wells, R. G. Pearcey, J. M. Connors, J. N. Winter, S. J. Horning, M. S. Djurfeldt, L. E. Shepherd, et al.
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma
Ann. Onc., October 1, 2007; 18(10): 1680 - 1684.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.